Ed Schuuring's Biography

Ed Schuuring, Professor in Molecular Oncological Pathology, University Medical Center Groningen

Prof Dr Ed Schuuring, PhD, senior clinical scientist in molecular pathology, University Medical Center Groningen, Groningen, The Netherlands

He finished his graduate training in Medical Biology in 1985 (cum laude) and PhD in 1993 in Molecular Biology at the Netherlands Cancer Institute (University of Amsterdam). In 1991 he received a staff position at the department of Pathology of LUMC in Leiden with focus on the identification of diagnostic relevant and predictive molecular markers for clinical outcome in breast cancer and BNHL lymphoma, and coordinated the introduction of molecular diagnostic pathology. In 2001 he moved to the department of Pathology of the UMCG in Groningen. His research focuses on the identification of prognostic/predictive epigenetic and molecular markers for clinical outcome, response to (chemo) radiotherapy, gene-targeted therapy and treatment-resistance in lung and head&neck cancer, as well as for the early detection of cervical cancer in scrapings. He was/is (co-) project leader on >31 research projects (ZONMW-COIN, ZONMW-PATH, NKB-KWF) and (co-) author of > 220 papers in peer-reviewed journals.

In addition to research, he is heading the laboratory of molecular pathology at UMCG for the region North-Netherlands. Since 1997 he is active in (inter)national committees and advisory boards on implementing molecular diagnostic pathology and active member in External Quality Assessment (Euroclonality, SKML, ESP, QCMD, IQNPath) by organizing international proficiency testing for mutations in EGFR, ALK, KRAS, ROS, MET and HPV in tissue biopsies and ctDNA from blood plasma. He is co-author on various international guidelines in Molecular Pathology. In October 2011 he was appointed full professor in “Molecular Oncological Pathology” and in July 2013 registered as Clinical Scientist in Molecular Pathology (KMBP) by the Dutch Society for Pathology. He has several collaborations with biotech companies in clinical trials or to develop companion diagnostics (Abbott, BMS, Biocartis, Roche, Hologic, Boeringer Ingelheim, CC Diagnostics). He acts regular upon invitation of companies as consultant, advisor or speaker regarding new development in molecular diagnostics (e.g. Amgen, Abbott, Astrazeneca, BMS, Bayer, Illumina, Biocartis, Novartis, Roche, Pfizer). He is member of the Dutch Society of Pathology (president of the section Clinical, Molecular and Experimental Pathology), American Association of Cancer Research, Dutch Society of Oncology, American Society of Clinical Oncology, European Society of Pathology and Association of Molecular Pathology.

Please find more details on my research and publications on http://www.rug.nl/staff/e.m.d.schuuring/ and information on Molecular Pathology on www.moloncopath.nl and www.pathology.nl